The disclosure of the annual report performance forecast of the pharmaceutical company was just in time, and another CRO company expected a substantial increase in performance

The disclosure of the performance forecast in the annual report of the pharmaceutical company was just at the time.
On January 24, another CRO company disclosed the performance forecast for 2021, and it is expected that the performance will increase significantly, and the net profit may double
.
On January 24, Boji Pharmaceutical released the 2021 annual report performance forecast, saying that it is expected to achieve a net profit of 37 million to 48 million yuan from 2021-01-01 to 2021-12-31, an increase of 117.
79% to 182.
54%, and the same period last year.
Realized a net profit of 16.
9886 million yuan
.
As for the main reasons for the change in performance in 2021, Boji Pharmaceutical stated that in 2021, the company's research projects will be steadily advanced, and the company's main business income will increase compared with the same period of the previous year, resulting in a higher net profit attributable to shareholders of listed companies in 2021.
year-on-year growth
.
In addition, in 2021, the company expects that the impact of non-recurring gains and losses on the net profit attributable to shareholders of listed companies will be about 10 million yuan to 16 million yuan
.
According to the data, Boji Pharmaceutical is a professional CRO service provider, mainly providing full-process "one-stop" CRO services for domestic and foreign pharmaceutical companies and other research institutions for the R&D and production of new drugs and medical devices
.
In 2021, the overall CRO industry will maintain a high prosperity, which will drive the performance of related companies to increase significantly
.
Up to now, a large number of companies in the CRO industry, such as WuXi AppTec and Tigermed, have disclosed their 2021 performance forecasts, and the overall performance is improving
.
For example, recently, WuXi AppTec, which provides R&D and production services for global pharmaceutical companies and other companies, released a 2021 performance forecast: It is estimated that in 2021, WuXi AppTec is expected to make a profit of 4.
973 billion yuan to 5.
032 billion yuan, a year-on-year increase of about 70%
.
WuXi PharmaTech said that the company's chemical business and testing business have achieved strong growth, and the impact of non-recurring gains and losses has resulted in a significant year-on-year increase in net profit
.
On the evening of January 21, Kanglong Chemical disclosed its 2021 annual performance forecast
.
The company expects to achieve revenue of 7.
341 billion yuan to 7.
495 billion yuan in 2021, a year-on-year increase of 43%-46%
.
Regarding the changes in performance, Kanglong Chemical said that in terms of main business, during the reporting period, the company's business plan was carried out in an orderly manner.
In 2021, the main business income will grow steadily, the scale and operational efficiency of mature service lines will gradually improve, and profitability will increase
.
Zhaoyan New Drug released its performance forecast on January 20
.
It is estimated that the net profit attributable to shareholders of listed companies in 2021 is expected to increase by about 227 million yuan to 259 million yuan compared with the same period of the previous year, an increase of about 72.
3% to 82.
3% year-on-year
.
During the reporting period, the company established and standardized the industry's innovative drug evaluation technology platform; the company's laboratory capacity utilization rate continued to increase, ensuring the efficient execution of orders in hand; the supply side also provided strong support for performance growth
.
Yabao Pharmaceutical announced on January 18 that it is expected to achieve a net profit of 165 million to 190 million yuan attributable to shareholders of listed companies in 2021, a year-on-year increase of 53.
68% to 76.
96%
.
It is reported that in 2021, the company will focus on high-margin core products and increase promotion efforts.
The revenue of high-margin products such as Ding Guier umbilical paste, swelling and pain relief paste, barley spleen gel and children's clearing throat and antipyretic oral liquid have achieved great growth; Due to the impact of the epidemic, the company's net profit base in 2020 is small, resulting in a larger increase in the current period's performance compared with the same period of the previous year
.
Medicilon released its earnings forecast on January 18
.
It is expected that the net profit attributable to owners of the parent company will be between 278 million and 291 million yuan in 2021, a year-on-year increase of 115% to 125%
.
It is understood that the company's new orders in 2021 will increase by about 88% compared with the same period of the previous year, and the company's operating income is expected to increase by about 78% compared with the same period of the previous year
.
On January 12, Tigermed, a contract research organization (CRO) that focuses on providing professional services for the whole process of clinical trials for new drug research and development, disclosed its performance forecast
.
The company expects a profit of 2.
624 billion yuan to 3.
027 billion yuan in 2021, an increase of 50%-73% over the same period of the previous year
.
During the reporting period, the company's main business continued to grow.
It is expected that the operating income and net profit attributable to shareholders of the listed company in 2021 will both increase compared with the same period of the previous year
.